Patents by Inventor Danielle Benoit

Danielle Benoit has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210330599
    Abstract: The present invention relates to compositions and methods to treat and/or prevent biofilms and biofilm related diseases. The invention comprises a nanoparticle carrier (NPC) and at least one therapeutic agent therein. The NPC binds within biofilm and to surfaces at risk for biofilm formation and accumulation while providing local, sustained, enhanced and controlled delivery of the therapeutic agent, when triggered for release. In one embodiment, the NPC comprises pH-responsive elements that allows for specific delivery of the therapeutic agent when the local environment dictates that the agent should be delivered precisely when it is most needed.
    Type: Application
    Filed: August 1, 2017
    Publication date: October 28, 2021
    Inventors: Danielle BENOIT, Hyun KOO
  • Publication number: 20200147121
    Abstract: Provided herein are micellic assemblies comprising a plurality of copolymers. In certain instances, micellic assemblies provided herein are pH sensitive particles.
    Type: Application
    Filed: September 23, 2019
    Publication date: May 14, 2020
    Applicants: University of Washington, GENEVANT SCIENCES GMBH
    Inventors: Patrick S. Stayton, Allan S. Hoffman, Anthony Convertine, Craig L. Duvall, Danielle Benoit, Robert Overell, Paul H. Johnson, Anna S. Gall, Mary G. Prieve, Amber E.E. Paschal, Charbel Diab, Priyadarsi De
  • Patent number: 10420790
    Abstract: Provided herein are micellic assemblies comprising a plurality of copolymers. In certain instauces, micellic assemblies provided herein are pH sensitive particles.
    Type: Grant
    Filed: April 27, 2017
    Date of Patent: September 24, 2019
    Assignees: University of Washington, GENEVANT SCIENCES GMBH
    Inventors: Patrick S. Stayton, Allan S. Hoffman, Anthony Convertine, Craig L. Duvall, Danielle Benoit, Robert Overell, Paul H. Johnson, Anna S. Gall, Mary G. Prieve, Amber E. E. Paschal, Charbel Diab, Priyadarsi De
  • Patent number: 10195284
    Abstract: The present invention provides compositions and methods for providing controllable local delivery of a therapeutic agent to promote bone formation. In certain embodiments, the invention is used as a treatment for a subject with osteoporosis, bone cancer or bone fracture. The invention provides a therapeutic agent that is tethered to a polymer to form a therapeutic-tethered macromer, where the therapeutic agent is controllably released from the conjugate by degradation of the tether. In certain embodiments, the therapeutic agent is an inhibitor of GSK3?. In certain embodiments, the composition of the invention is specifically targeted to a site in need of bone formation or treatment.
    Type: Grant
    Filed: September 26, 2016
    Date of Patent: February 5, 2019
    Assignee: UNIVERSITY OF ROCHESTER
    Inventors: Danielle Benoit, J. Edward Puzas, Maureen Newman, Tzong-Jen Sheu, Benjamin Frisch
  • Publication number: 20180171056
    Abstract: Described herein are copolymers, and methods of making and utilizing such copolymers. Such copolymers have at least two blocks: a first block that has at least one unit that is hydrophilic at physiologic pH, and a second block that has hydrophobic groups. This second block further has at least one unit with a group that is anionic at about physiologic pH. The described copolymers are disruptive of a cellular membrane, including an extracellular membrane, an intracellular membrane, a vesicle, an organelle, an endosome, a liposome, or a red blood cell. Preferably, in certain instances, the copolymer disrupts the membrane and enters the intracellular environment. In specific examples, the copolymer is endosomolytic.
    Type: Application
    Filed: November 30, 2017
    Publication date: June 21, 2018
    Inventors: Patrick S. Stayton, Allan S. Hoffman, Anthony J. Convertine, Danielle Benoit, Craig L. Duvall, Paul H. Johnson, Anna S. Gall
  • Patent number: 9949950
    Abstract: The present invention provides compositions and methods for providing controllable local delivery of a therapeutic agent to promote bone formation. In certain embodiments, the invention is used as a treatment for a subject with osteoporosis, bone cancer or bone fracture. The invention provides a therapeutic agent that is tethered to a polymer to form a therapeutic-tethered macromer, where the therapeutic agent is controllably released from the conjugate by degradation of the tether. In certain embodiments, the therapeutic agent is an inhibitor of GSK3?. In certain embodiments, the composition of the invention is specifically targeted to a site in need of bone formation.
    Type: Grant
    Filed: September 14, 2015
    Date of Patent: April 24, 2018
    Assignee: UNIVERSITY OF ROCHESTER
    Inventors: Danielle Benoit, J. Edward Puzas, Maureen Newman, Tzong-Jen Sheu
  • Patent number: 9862792
    Abstract: Described herein are copolymers, and methods of making and utilizing such copolymers. Such copolymers have at least two blocks: a first block that has at least one unit that is hydrophilic at physiologic pH, and a second block that has hydrophobic groups. This second block further has at least one unit with a group that is anionic at about physiologic pH. The described copolymers are disruptive of a cellular membrane, including an extracellular membrane, an intracellular membrane, a vesicle, an organelle, an endosome, a liposome, or a red blood cell. Preferably, in certain instances, the copolymer disrupts the membrane and enters the intracellular environment. In specific examples, the copolymer is endosomolytic.
    Type: Grant
    Filed: September 13, 2016
    Date of Patent: January 9, 2018
    Assignees: University of Washington, PhaseRx, Inc.
    Inventors: Patrick S. Stayton, Allan S. Hoffman, Anthony J. Convertine, Danielle Benoit, Craig L. Duvall, Paul H. Johnson, Anna S. Gall
  • Publication number: 20170239360
    Abstract: Provided herein are micellic assemblies comprising a plurality of copolymers. In certain instauces, micellic assemblies provided herein are pH sensitive particles.
    Type: Application
    Filed: April 27, 2017
    Publication date: August 24, 2017
    Applicants: University of Washington, PhaseRx, Inc.
    Inventors: Patrick S. Stayton, Allan S. Hoffman, Anthony Convertine, Craig L. Duvall, Danielle Benoit, Robert Overell, Paul H. Johnson, Anna S. Gall, Mary G. Prieve, Amber E.E. Paschal, Charbel Diab, Priyadarsi De
  • Patent number: 9662403
    Abstract: Provided herein are micellic assemblies comprising a plurality of copolymers. In certain instances, micellic assemblies provided herein are pH sensitive particles.
    Type: Grant
    Filed: March 2, 2016
    Date of Patent: May 30, 2017
    Assignees: University of Washington, PhaseRx, Inc.
    Inventors: Patrick S. Stayton, Allan S. Hoffman, Anthony Convertine, Craig L. Duvall, Danielle Benoit, Robert Overell, Paul H. Johnson, Anna S. Gall, Mary G. Prieve, Amber E. E. Paschal, Charbel Diab, Priyadarsi De
  • Publication number: 20170096517
    Abstract: Described herein are copolymers, and methods of making and utilizing such copolymers. Such copolymers have at least two blocks: a first block that has at least one unit that is hydrophilic at physiologic pH, and a second block that has hydrophobic groups. This second block further has at least one unit with a group that is anionic at about physiologic pH. The described copolymers are disruptive of a cellular membrane, including an extracellular membrane, an intracellular membrane, a vesicle, an organelle, an endosome, a liposome, or a red blood cell. Preferably, in certain instances, the copolymer disrupts the membrane and enters the intracellular environment. In specific examples, the copolymer is endosomolytic.
    Type: Application
    Filed: September 13, 2016
    Publication date: April 6, 2017
    Applicants: University of Washington, PhaseRx, Inc.
    Inventors: Patrick S. Stayton, Allan S. Hoffman, Anthony J. Convertine, Danielle Benoit, Craig L. Duvall, Paul H. Johnson, Anna S. Gall
  • Publication number: 20170072062
    Abstract: The present invention provides compositions and methods for providing controllable local delivery of a therapeutic agent to promote bone formation. In certain embodiments, the invention is used as a treatment for a subject with osteoporosis, bone cancer or bone fracture. The invention provides a therapeutic agent that is tethered to a polymer to form a therapeutic-tethered macromer, where the therapeutic agent is controllably released from the conjugate by degradation of the tether. In certain embodiments, the therapeutic agent is an inhibitor of GSK3?. In certain embodiments, the composition of the invention is specifically targeted to a site in need of bone formation or treatment.
    Type: Application
    Filed: September 26, 2016
    Publication date: March 16, 2017
    Inventors: Danielle Benoit, J. Edward Puzas, Maureen Newman, Tzong-Jen Sheu
  • Patent number: 9566247
    Abstract: The present invention relates to compositions and methods to treat and/or prevent biofilms and biofilm related diseases. The invention comprises a nanoparticle carrier (NPC) and at least one therapeutic agent therein. The NPC binds within biofilm and to surfaces at risk for biofilm formation and accumulation while providing local, sustained, enhanced and controlled delivery of the therapeutic agent, when triggered for release. In one embodiment, the NPC comprises pH-responsive elements that allows for specific delivery of the therapeutic agent when the local environment dictates that the agent should be delivered precisely when it is most needed.
    Type: Grant
    Filed: February 25, 2014
    Date of Patent: February 14, 2017
    Assignee: University of Rochester
    Inventors: Hyun Koo, Danielle Benoit, Marlise I. Klein, Megan L. Falsetta Wood
  • Patent number: 9476063
    Abstract: Described herein are copolymers, and methods of making and utilizing such copolymers. Such copolymers have at least two blocks: a first block that has at least one unit that is hydrophilic at physiologic pH, and a second block that has hydrophobic groups. This second block further has at least one unit with a group that is anionic at about physiologic pH. The described copolymers are disruptive of a cellular membrane, including an extracellular membrane, an intracellular membrane, a vesicle, an organelle, an endosome, a liposome, or a red blood cell. Preferably, in certain instances, the copolymer disrupts the membrane and enters the intracellular environment. In specific examples, the copolymer is endosomolytic.
    Type: Grant
    Filed: May 13, 2009
    Date of Patent: October 25, 2016
    Assignees: University of Washington, PhaseRx, Inc.
    Inventors: Patrick S. Stayton, Allan S. Hoffman, Anthony J. Convertine, Danielle Benoit, Craig L. Duvall, Paul H. Johnson, Anna S. Gall
  • Publication number: 20160250338
    Abstract: Provided herein are micellic assemblies comprising a plurality of copolymers. In certain instances, micellic assemblies provided herein are pH sensitive particles.
    Type: Application
    Filed: March 2, 2016
    Publication date: September 1, 2016
    Applicants: University of Washington, PhaseRx, Inc.
    Inventors: Patrick S. Stayton, Allan S. Hoffman, Anthony Convertine, Craig L. Duvall, Danielle Benoit, Robert Overell, Paul H. Johnson, Anna S. Gall, Mary G. Prieve, Amber E.E. Paschal, Charbel Diab, Priyadarsi De
  • Patent number: 9339558
    Abstract: Provided herein are micellic assemblies comprising a plurality of copolymers. In certain instances, micellic assemblies provided herein are pH sensitive particles.
    Type: Grant
    Filed: May 13, 2009
    Date of Patent: May 17, 2016
    Assignees: University of Washington, PhaseRx, Inc.
    Inventors: Patrick S. Stayton, Allan S. Hoffman, Anthony J. Convertine, Craig L. Duvall, Danielle Benoit, Robert W. Overell, Paul H. Johnson, Anna S. Gall, Mary G. Prieve, Amber E.E. Paschal, Charbel Diab, Priyadarsi De
  • Publication number: 20150374663
    Abstract: The present invention provides compositions and methods for providing controllable local delivery of a therapeutic agent to promote bone formation. In certain embodiments, the invention is used as a treatment for a subject with osteoporosis, bone cancer or bone fracture. The invention provides a therapeutic agent that is tethered to a polymer to form a therapeutic-tethered macromer, where the therapeutic agent is controllably released from the conjugate by degradation of the tether. In certain embodiments, the therapeutic agent is an inhibitor of GSK3?. In certain embodiments, the composition of the invention is specifically targeted to a site in need of bone formation.
    Type: Application
    Filed: September 14, 2015
    Publication date: December 31, 2015
    Applicant: UNIVERSITY OF ROCHESTER
    Inventors: DANIELLE BENOIT, EDWARD J. PUZAS, MAUREEN NEWMAN, TZONG-JEN SHEU
  • Publication number: 20150374634
    Abstract: The present invention relates to compositions and methods to treat and/or prevent biofilms and biofilm related diseases. The invention comprises a nanoparticle carrier (NPC) and at least one therapeutic agent therein. The NPC binds within biofilm and to surfaces at risk for biofilm formation and accumulation while providing local, sustained, enhanced and controlled delivery of the therapeutic agent, when triggered for release. In one embodiment, the NPC comprises pH-responsive elements that allows for specific delivery of the therapeutic agent when the local environment dictates that the agent should be delivered precisely when it is most needed.
    Type: Application
    Filed: February 25, 2014
    Publication date: December 31, 2015
    Applicant: UNIVERSITY OF ROCHESTER
    Inventors: Hyun Koo, Danielle Benoit, Marlise I. Klein, Megan L. Falsetta Wood
  • Patent number: 9193954
    Abstract: Provided is a method for increasing proliferation of mesenchymal stem cells. The method entails contacting the cells with 6-bromoindirubin-3?-oxime (BIO). This results in robust proliferation and “stemness” in a dose-dependent fashion, as indicated by the gene expression of two stem cell genes: Sox2 and Nanog.
    Type: Grant
    Filed: April 2, 2012
    Date of Patent: November 24, 2015
    Assignee: University of Rochester
    Inventors: Michael Hoffman, Danielle Benoit
  • Publication number: 20150238619
    Abstract: Provided herein are polymeric carriers suitable for the delivery of polynucleotides (e.g., oligonucleotides) and/or other therapeutic agents into a living cell.
    Type: Application
    Filed: February 24, 2015
    Publication date: August 27, 2015
    Applicants: PHASERX, INC., UNIVERSITY OF WASHINGTON
    Inventors: Patrick S. Stayton, Allan S. Hoffman, Anthony J. Convertine, Craig L. Duvall, Danielle Benoit, Robert Overell, Paul H. Johnson, Anna S. Gall, Mary G. Prieve, Amber E.E. Paschal, Charbel Diab, Priyadarsi De
  • Patent number: 9006193
    Abstract: Provided herein are polymeric carriers suitable for the delivery of polynucleotides (e.g. oligonucleotides) and/or other therapeutic agents into a living cell.
    Type: Grant
    Filed: May 13, 2009
    Date of Patent: April 14, 2015
    Assignees: University of Washington, PhaseRx, Inc.
    Inventors: Patrick S. Stayton, Allan S. Hoffman, Anthony J. Convertine, Craig L. Duvall, Danielle Benoit, Robert W. Overell, Paul H. Johnson, Anna S. Gall, Mary G. Prieve, Amber E. E. Paschal, Charbel Diab, Priyadarsi De